<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520946</url>
  </required_header>
  <id_info>
    <org_study_id>RAMTAS</org_study_id>
    <secondary_id>2017-004162-99</secondary_id>
    <nct_id>NCT03520946</nct_id>
  </id_info>
  <brief_title>RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients</brief_title>
  <acronym>RAMTAS</acronym>
  <official_title>A Phase IIb Study of RAMucirumab in Combination With TAS102 vs. TAS102 Monotherapy in Chemotherapy Refractory Metastatic Colorectal Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Trium Analysis Online GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interventional, prospective, randomized (1:1), controlled, open label, multicenter phase IIb
      study in patients with advanced metastatic colorectal cancer. The scope of the trial is to
      evaluate overall survival of either regimen (TAS102 +/- Ramucirumab) and evaluate safety and
      tolerability.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional, prospective, randomized (1:1), controlled, open label, multicenter
      phase IIb study in patients with advanced metastatic colorectal cancer. The scope of the
      trial is to evaluate overall survival of either regimen and evaluate safety and tolerability.

      Patients with advanced metastatic and inoperable, colorectal cancer who have progressed
      on/after or did not tolerate: fluoropyrimidines, oxaliplatin, irinotecan, anti-angiogenic
      therapies (bevacizumab, aflibercept, regorafenib or ramucirumab) and when indicated anti-EGFR
      (epidermal growth factor receptor) antibodies (cetuximab or panitumumab) will be included in
      this trial.

      Patients will be stratified by the duration of previous anti-angiogenic therapy ≥ or &lt;12
      months in total, BRAF V600E mutation status (mutation vs. wildtype), RAS mutation status
      (mutation vs. wildtype), and randomized 1:1 to receive either ramucirumab/TAS102 (arm A) or
      TAS102 (arm B). Concurrent use of other chemotherapy is not allowed.

      Two interim safety analyses will be conducted when 10 and 40 patients are fully documented in
      arm A after receiving 2 cycles (one 4-week cycle comprises ramucirumab 8mg/kg administered at
      d1 and d15 and TAS102 35mg/m2 p.o. twice daily administered on d1-5 and d8-12). The analysis
      will be reviewed by the lead coordinating investigator (Prof. Dr. Kasper) and members of the
      steering committee and then by the data safety monitoring board. It is not planned to
      discontinue recruitment for the interim safety analyses.

      Arm A (ramucirumab/TAS102) Patients randomized to arm A will receive ramucirumab 8 mg/kg iv
      over 60 min on d1+15, q4w and TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until
      progression or intolerance or completion of 6 cycles.

      Arm B (TAS102) Patients randomized to arm B will receive TAS102 35mg/m2 p.o. twice daily
      (BID) d1-5 and 8-12, q4w until progression, intolerance or completion of 6 cycles.

      In both arms, tumor assessments (CT or MRI) are performed before enrollment/randomization and
      then every 8 weeks (every 2nd cycle) during therapy and every 12 weeks during follow-up until
      progression/relapse, death or end of follow-up. A change from CT into MRI in the follow-up
      period is possible at any time.

      During treatment, clinical visits (blood cell counts, detection of toxicity) will be
      performed prior to every treatment dose of ramucirumab or every two weeks in arm B or if
      ramucirumab was discontinued in arm A. Safety of TAS102 +/- ramucirumab will be monitored
      continuously by careful monitoring of all adverse events (AEs) and serious adverse events
      (SAEs) reported. Every 4 weeks during therapy Quality of life (QoL) will be assessed using
      the European Organization for Research and Treatment of Cancer Quality of Life
      Questionnaire-C30 (EORTC-QLQ-C30) and the EuroQol 5 dimensions 5-level version (EQ-5D-5L).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Overall survival according to Kaplan-Meier</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>ORR defined as the proportion of patients with complete or partial remission according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>DCR defined as the proportion of patients with complete or partial remission and stable disease according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>PFS, defined as the time from enrollment/randomization to the first occurrence of progression, as determined by the investigator using CT criteria, or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) at different time points</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>OS rate at 6 and 12 months, defined as patients who are alive after at 6 and 12 months, respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (ORR)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Efficacy (ORR) in patients who develop neutropenia grade ≥2 (ANC ≤1500/μl) in cycle 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (PFS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Efficacy (PFS) in patients who develop neutropenia grade ≥2 (ANC ≤1500/μl) in cycle 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (OS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Efficacy (OS) in patients who develop neutropenia grade ≥2 (ANC ≤1500/μl) in cycle 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life I (QoL)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Quality of life (QoL) as measured by EORTC-QLQ-C30 at d1 of each cycle and on EOT (end of treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life II (QoL)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Quality of life (QoL) as measured by EQ-5D-5L at d1 of each cycle and on EOT.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Explorative: Overall response rate (ORR)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>ORR according to gene expression, mutational profiles and plasma biomarkers</description>
  </other_outcome>
  <other_outcome>
    <measure>Explorative: Overall survival (OS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>OS according to gene expression, mutational profiles and plasma biomarkers</description>
  </other_outcome>
  <other_outcome>
    <measure>Explorative: Progression-free survival (PFS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>PFS according to gene expression, mutational profiles and plasma biomarkers</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A (ramucirumab + TAS102)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to arm A will receive ramucirumab 8 mg/kg iv over 60 min on d1+15, q4w and TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until progression or intolerance or completion of 6 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (TAS102 only)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to arm B will receive TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until progression, intolerance or completion of 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramucirumab</intervention_name>
    <description>8 mg/kg iv over 60 min on d1+15, q4w</description>
    <arm_group_label>Arm A (ramucirumab + TAS102)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS 102</intervention_name>
    <description>35mg/m2 p.o. twice daily (BID) d1-5 and d8-12, q4w</description>
    <arm_group_label>Arm A (ramucirumab + TAS102)</arm_group_label>
    <arm_group_label>Arm B (TAS102 only)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Metastatic and inoperable, colorectal cancer who has progressed on/after or did not
             tolerate: fluoropyrimidines, oxaliplatin, irinotecan, anti-angiogenic therapies
             (bevacizumab, aflibercept, regorafenib or ramucirumab) and if indicated anti-EGFR
             antibodies (cetuximab or panitumumab)

          2. Signed informed consent before start of specific protocol procedure

          3. Histologically or cytologically documented diagnosis of adenocarcinoma of the colon or
             rectum

          4. Presence of at least one measurable site of disease following RECIST 1.1 criteria

          5. ECOG (Eastern Cooperative Oncology Group) performance 0-1

          6. Known RAS and BRAF V600E mutational status

          7. Life expectancy of at least 3 months

          8. Adequate hematological, hepatic and renal function parameters:

               1. Leukocytes ≥3000/mm³, platelets ≥100,000/mm³, neutrophil count (ANC) ≥1500/μL,
                  hemoglobin ≥9 g/dL (5.58 mmol/L)

               2. Adequate coagulation function as defined by International Normalized Ratio (INR)
                  ≤1.5, and a partial thromboplastin time (PTT) ≤5 seconds above the ULN (upper
                  limit of normal) (unless receiving anticoagulation therapy). Patients receiving
                  warfarin/phenprocoumon must be switched to low molecular weight heparin and have
                  achieved a stable coagulation profile prior to first dose of protocol therapy

               3. Serum creatinine ≤1.5 x upper limit of normal

               4. Urinary protein ≤1+ on dipstick or routine urinalysis (UA; if urine dipstick or
                  routine analysis is ≥2+, a 24-hour urine collection for protein must demonstrate
                  &lt;1000 mg of protein in 24 hours to allow participation in this protocol)

               5. Bilirubin ≤1.5 x upper limit of normal, AST and ALT ≤3.0 x upper limit of normal,
                  ≤5xULN if liver metastasis present, alkaline phosphatase ≤6 x upper limit of
                  normal

          9. Patient able and willing to provide written informed consent and to comply with the
             study protocol

         10. Female and male patients ≥18 and ≤70 years. Patients in reproductive age must be
             willing to use adequate contraception during the study and for 7 months after the end
             of ramucirumab treatment (appropriate contraception is defined as surgical
             sterilization (e.g., bilateral tubal ligation, vasectomy), hormonal contraception
             (implantable, patch, oral), and double-barrier methods (any double combination of:
             IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap)).
             Female patients with childbearing potential need to have a negative pregnancy test
             within 7 days before study start (There are no data that indicate special gender
             distribution. Therefore, patients will be enrolled in the study gender-independently.)

        Exclusion Criteria:

          1. Known hypersensitivity against ramucirumab or TAS102

          2. Other known contraindications against ramucirumab, TAS102, or other anti-angiogenic
             therapies

          3. Prior therapy with TAS102

          4. Drug-related severe adverse events upon pretreatment with antiangiogenic drugs that
             would require permanent discontinuation and not allow re-challenge with the same class
             of drug (i.e. ramucirumab) such as noncontrollable severe hypertension or
             thromboembolic events

          5. Major surgery within 4 weeks of starting therapy within this study, or minor
             surgery/subcutaneous venous access device placement within 7 days prior to first dose
             of protocol therapy

          6. Symptomatic brain metastasis

          7. Clinically significant cardiovascular disease

               -  NYHA&gt;II°, myocardial infarction within 6 months prior study entry

               -  Known clinically significant valvular defect

               -  Uncontrolled or poorly-controlled hypertension (&gt;160 mmHg systolic or &gt;100 mmHg
                  diastolic for &gt;4 weeks) despite standard medical management

               -  Any arterial thromboembolic events, including but not limited to myocardial
                  infarction, transient ischemic attack, cerebrovascular accident, or unstable
                  angina, within 6 months prior to first dose of protocol therapy

               -  History of deep vein thrombosis (DVT), pulmonary embolism (PE), or any other
                  significant thromboembolism (venous port or catheter thrombosis or superficial
                  venous thrombosis are not considered &quot;significant&quot;) during the 3 months prior to
                  first dose of protocol therapy

          8. Active clinically serious infections (&gt; grade 2 NCI-CTC version 4.0)

          9. Chronic inflammatory bowel disease

         10. History of uncontrolled HIV infection or chronic hepatitis B or C

         11. Patients with evidence of bleeding diathesis

         12. Grade 3-4 GI bleeding within 3 months prior to first dose of protocol therapy

         13. Receiving chronic antiplatelet therapy, including aspirin (once daily aspirin use
             (maximum dose 325 mg/day) is permitted), nonsteroidal anti-inflammatory drugs
             (including ibuprofen, naproxen, and others), dipyridamole or clopidogrel, or similar
             agents

         14. History of gastrointestinal perforation or fistulae in past 6 months or risk factors
             for perforation

         15. Serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to first
             dose of protocol therapy

         16. Past or current history of other malignancies not curatively treated and without
             evidence of disease for more than 5 years, except for curatively treated basal cell
             carcinoma of the skin and in situ carcinoma of the cervix or bladder, or
             low/intermediate risk prostate cancer (Gleason score ≤7) with normal PSA levels

         17. Any condition that could jeopardize the safety of the patient and their compliance of
             the study

         18. Medical, psychological or social conditions that may interfere with the participation
             in the study

         19. Cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) and a
             history of hepatic encephalopathy or ascites.

             Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics
             or paracentesis

         20. On-treatment participation in another clinical study or received investigational drug
             therapy in the period 30 days prior to inclusion and during the study

         21. Subject pregnant or breast feeding, or planning to become pregnant within 7 months
             after the end of treatment

         22. Patients in a closed institution according to an authority or court decision (AMG §
             40, Abs. 1 No. 4)

         23. Any other concurrent antineoplastic treatment including irradiation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Kasper, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>West German Cancer Center - University Hospital Essen, University Duisburg-Essen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Salah-Eddin Al-Batran, Prof. Dr.</last_name>
    <phone>+49697601</phone>
    <phone_ext>4420</phone_ext>
    <email>albatran@ikf-khnw.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gerrit zur Hausen, Dr.</last_name>
    <phone>+49697601</phone>
    <phone_ext>4518</phone_ext>
    <email>zurhausen.gerrit@ikf-khnw.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum Altenburger Land GmbH</name>
      <address>
        <city>Altenburg</city>
        <zip>04600</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Armin Schulz-Abelius, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Gesundheitszentrum St. Marien GmbH</name>
      <address>
        <city>Amberg</city>
        <zip>922241</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ludwig Fischer von Weikersthal, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Bad Saarow</name>
      <address>
        <city>Bad Saarow</city>
        <zip>15526</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Pink, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susen Burock, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Seestrasse</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Schmittel, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St.-Johannes-Hospital</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Volker Hagen, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dirk Graf, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Kasper, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest GmbH</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thorsten O Goetze, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Stein, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arndt Vogel, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vincentius-Diakonissen-Kliniken gAG</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Kolov, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Albrecht Hoffmeister, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigsburg</name>
      <address>
        <city>Ludwigsburg</city>
        <zip>71640</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Angermeier, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tagestherapiezentrum am ITM Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ralf D Hofheinz, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johannes Weslin Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans J Tischler, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken Maria Hilf GmbH</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ullrich Graeven, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München-Großhadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Volker Heinemann, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriele Siegler, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Onkologie Ravensburg</name>
      <address>
        <city>Ravensburg</city>
        <zip>88212</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tobias Dechow, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leopoldina Krankenhaus</name>
      <address>
        <city>Schweinfurt</city>
        <zip>97422</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan Kanzler, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Klinik Dr. Hancken GmbH</name>
      <address>
        <city>Stade</city>
        <zip>21680</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johannes Meiler, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Wilhelmshaven</name>
      <address>
        <city>Wilhelmshaven</city>
        <zip>26389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tanja Trarbach, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hämatologisch-Onkologische Praxis</name>
      <address>
        <city>Würselen</city>
        <zip>52146</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Maintz, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>April 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2018</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>ramucirumab</keyword>
  <keyword>tas102</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramucirumab</mesh_term>
    <mesh_term>Trifluridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

